FDA Draft Guidance on Early-Phase IND Protocols for Solid Tumors
Published November 2026 — A summary of the FDA's draft recommendations for first-in-human and early-phase oncology protocols, issued in support of Operation TrialBlazer, and what they mean for sites running Phase I studies.
A Protocol-Level Guide for First-in-Human Oncology Trials
In November 2026 the FDA’s Oncology Center of Excellence, together with CDER and CBER, issued a draft guidance titled “Early-Phase IND Protocol Recommendations for Solid Tumors.” It is intended to help sponsors design first-in-human and other early-phase studies of investigational drugs and biologics for solid tumors.
The FDA has tied the document to Operation TrialBlazer, an HHS initiative launched as a pilot in mid-June 2026. TrialBlazer groups together measures meant to speed clinical development from the IND stage through late-stage pivotal trials and to keep early clinical research in the United States.
The guidance is a draft and is not for implementation. Comments can be submitted to docket FDA-2026-D-13432 on regulations.gov until January 11, 2027.
Key Recommendations
The draft works through the main design decisions in an early-phase solid tumor protocol.
The draft cautions that overly restrictive eligibility criteria can slow recruitment, limit access to early-phase trials, and produce results that do not generalize to the intended patient population. Protocols should generally avoid upper age limits, and a sponsor that proposes one is expected to justify it.
The primary objective of a first-in-human dose-escalation trial should be to assess safety and tolerability. Dose identification, pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers, exposure-response relationships, food effects, drug interactions, and preliminary activity can be secondary objectives.
Sponsors should minimize the number of patients exposed to a drug that is likely ineffective or significantly toxic. The statistical analysis plan should justify the maximum sample size of each expansion cohort, and the draft addresses selecting the dose to carry into Phase 2.
The draft states that single-arm trials do not adequately characterize time-to-event endpoints such as overall survival or progression-free survival, and that a randomized study is generally necessary to evaluate them. Response rate remains the usual preliminary activity measure in single-arm cohorts.
Where selecting patients by biomarker is essential to the safe and effective use of the product, an in vitro companion diagnostic may need to be developed and validated. Sponsors are advised to consult the Center for Devices and Radiological Health early.
The guidance applies to investigational drugs and biologics for solid tumors and was issued by the Oncology Center of Excellence with CDER and CBER. It does not cover hematologic malignancies.
Site-Level Implications
The guidance is addressed to sponsors, but the protocols it shapes are run at sites. These are the changes early-phase oncology sites are most likely to see if the draft is finalized in its current form.
If sponsors follow the eligibility recommendations, early-phase protocols will admit more older patients and more patients with comorbidities or prior therapies. Sites should plan for screening and safety monitoring of a less narrowly selected population.
With safety and tolerability as the stated primary objective, dose-escalation studies place a premium on timely adverse event assessment, dose-limiting toxicity reporting, and investigator availability for cohort review calls.
The list of acceptable secondary objectives implies intensive sample collection. Sites need reliable processes for timed draws, processing, and shipment, and enough staff to perform them without deviations.
The draft's position on time-to-event endpoints points toward randomized cohorts appearing earlier. Sites accustomed to single-arm expansion cohorts should be ready for randomization, blinding where used, and the consent conversation that goes with it.
Where a companion diagnostic is in development, sites may be asked to support tissue or blood collection for assay validation alongside enrollment testing, with turnaround times that affect the screening window.
Expansion cohorts with a pre-specified maximum sample size give sites a clearer enrollment target per cohort, which helps with feasibility responses and staffing plans.
What This Means for Sponsors
Sponsors preparing an IND for a solid tumor program in 2027 should read the draft against their protocol template now. The eligibility section is the most immediately actionable: exclusions carried over from earlier protocols by habit, including upper age limits, are the ones the FDA is signaling it will question.
The draft also reinforces the direction the agency has taken on dose selection in oncology. A sponsor should expect to explain how the dose taken into Phase 2 was chosen and why each expansion cohort is the size it is. Programs that plan to rely on time-to-event endpoints should plan for a randomized comparison.
Site selection follows from these choices. Broader eligibility widens the pool of sites that can contribute patients, while intensive sampling and close safety review still call for sites with real Phase I capability.
Early-Phase Oncology in the Clinitiative Network
Oncology is one of the therapeutic areas represented across the Clinitiative network, which supports Phase I through Phase IV studies. Sponsors designing an early-phase solid tumor protocol can submit it for feasibility review, and we will identify network sites whose patient populations and Phase I capabilities fit the design.
Designing an Early-Phase Oncology Study?
Submit your protocol for a feasibility assessment across our oncology sites.